Matrix-Associated EGF Changes Chemotherapy Responses in MCF-7 Breast-Cancer Spheroids
MCF-7 cells grown in EGF-loaded alginate cryogels showed increased proliferation and reduced sensitivity to several drugs. The study links those changes to matrix and growth-factor signaling, with gene-expression and metabolite associations supplying hypotheses rather than patient-response validation.
A Cell-Line Model of Growth-Factor Presentation
Huazhong University of Science and Technology researchers investigated whether presenting epidermal growth factor (EGF) within a three-dimensional matrix changes breast-cancer behavior and drug response. The model used the established MCF-7 cell line in porous calcium-crosslinked alginate cryogels. These are cell-line spheroids, rather than organoids generated from patient tumor samples.
The cryogel acted as both a structural support and an EGF reservoir. In the reported concentration comparison, 600 ng/mL supported spheroid formation better than 60 ng/mL, while 3 μg/mL inhibited growth and caused cell loss. Approximately half of loaded EGF was released within 48 hours, and about 40% remained after seven days. The matrix-associated condition therefore involved both retained and released growth factor.
Subsequent experiments compared EGF-loaded and unloaded cryogels. Microscopy and material characterization did not find a significant pore-size difference between the tested EGF-loading groups, helping separate growth-factor effects from a gross change in scaffold porosity.
A separate Matrigel comparison at six days found a similar mean spheroid area but a narrower size distribution in the EGF-loaded cryogel. This structural comparison did not establish equal drug sensitivity between matrices. The release experiment was also performed without cells, so it characterized the material reservoir rather than cellular uptake or receptor-level exposure.
Proliferation, Migration and Apoptosis Change Together
EGF-loaded cultures formed larger spheroids and had a higher Ki-67-positive fraction: 80.9 ± 3.3%, compared with 41.3 ± 3.8% without EGF. Cells recovered from the spheroids also migrated more in Transwell assays. That migration experiment measured dissociated cells after culture, rather than observing metastasis in an intact tumor.
The EGF condition showed lower E-cadherin and higher vimentin expression, consistent with an epithelial-to-mesenchymal-associated shift. Apoptosis-associated staining was reduced, and the annexin-V/propidium-iodide assay gave apoptotic fractions of 19.9 ± 3.8% with EGF versus 26.6 ± 3.9% without it. The findings connect the matrix condition to several measured phenotypes without establishing clinical metastatic behavior.
Drug Sensitivity Is Reduced Across Several Mechanisms
Three-day drug-response testing covered doxorubicin, epirubicin, 5-fluorouracil and paclitaxel. Doxorubicin IC50 increased from 1.93 ± 0.10 to 4.53 ± 0.52 μM with EGF loading. Epirubicin values increased from 0.76 ± 0.08 to 2.64 ± 0.35 μM, and 5-fluorouracil values from 9.23 ± 0.94 to 13.94 ± 1.39 μM.
Paclitaxel produced an IC50 of 2.32 ± 0.40 μM in unloaded cryogels. An IC50 could not be estimated in the EGF-loaded group because cell loss was insufficient over the tested range. This is a bounded concentration-series result, rather than a measured unlimited resistance level.
Expression of the transporter-associated gene ABCG2 increased, while H1-2 expression decreased. These findings suggest possible contributors to the altered response, but expression measurements alone do not quantify drug efflux or DNA-repair capacity. Paclitaxel also acts on microtubules, so the four-drug pattern spans more than one drug mechanism.
Profiling Suggests Interacting Signaling and Metabolic Programs
Transcriptomic comparisons included unloaded three-dimensional cultures, EGF-loaded cultures and two-dimensional cells receiving soluble EGF. The profiles differed across these settings, supporting an effect of both matrix context and growth-factor presentation. EGF-loaded cultures showed higher secretion of IL-18, IL-33 and GDF-15, increased FN1 expression and increased activation-associated measurements in the PI3K–AKT–mTOR network.
Metabolomic analysis found 83 differential metabolites, including increased aspartate. GOT2 messenger RNA was also increased, and gene–metabolite correlations linked the expression and metabolic profiles. The study did not directly measure flux through GOT2 or establish aspartate as a clinically validated biomarker of resistance.
Quantitative experiments used three replicate samples; the main text does not specify whether the accompanying dispersion values are standard deviations or standard errors. The work demonstrates that a controllable matrix condition can alter several pharmacological and cellular measurements within one breast-cancer cell line. Extending that finding to tumor diversity, patient response or a causal signaling-to-metabolism sequence requires evidence beyond the profiled associations in this model.